STOCK TITAN

Ionis Pharmaceuticals, Inc. - IONS STOCK NEWS

Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a leading biotechnology company headquartered in Carlsbad, California. Founded in 1989, Ionis has been pioneering the discovery and development of antisense drugs, with an impressive portfolio of over 1300 patents. Ionis focuses on creating innovative RNA-targeted therapies for complex diseases, particularly in the areas of cardiovascular, metabolic, neurological, and rare genetic disorders.

Ionis has successfully brought several groundbreaking medicines to market. Notable achievements include the development of Spinraza, in collaboration with Biogen, which was launched in 2016 to treat spinal muscular atrophy, a rare neuromuscular disorder. In 2023, Biogen also launched Qalsody for ALS, further extending the impact of Ionis' antisense technology.

Through its cardiovascular-focused subsidiary, Akcea Therapeutics, Ionis has introduced drugs like Tegsedi for ATTR amyloidosis and Waylivra in Europe for cardiology indications. The company continues to advance its pipeline with promising candidates such as olezarsen, an investigational RNA-targeted therapy for familial chylomicronemia syndrome (FCS). Ionis' ongoing Phase 3 trials for olezarsen have shown promising results, with significant reductions in triglyceride levels and improvements in related health outcomes.

Ionis' commitment to innovation and patient care is also evident in its robust financial health and strategic partnerships. With a deep understanding of disease biology and cutting-edge technology, Ionis continues to drive advancements in RNA therapies and gene editing, aiming to deliver life-changing medicines for patients around the world.

Recently, Ionis announced positive clinical trial results for several of its investigational drugs and plans to pursue regulatory approvals for these therapies. The company's pipeline is well-positioned to address unmet medical needs in various therapeutic areas, promising a steady flow of new treatments in the coming years.

For more detailed information about Ionis Pharmaceuticals, its products, and career opportunities, visit their official website at www.ionispharma.com.

Rhea-AI Summary

Ionis Pharmaceuticals (Nasdaq: IONS) announced its participation in two upcoming virtual investor conferences. The events include the Stifel 2021 Healthcare Conference on November 15, 2021, and the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021. Details regarding presentation times may change, and updates will be available on their website. A live webcast of the presentations will be accessible in the Investors & Media section of Ionis' site, with replays available within 48 hours. For over 30 years, Ionis has led in RNA-targeted therapy, emphasizing their commitment to innovative treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
conferences
-
Rhea-AI Summary

Ionis Pharmaceuticals announced positive results from the Phase 2 study of donidalorsen, its investigational antisense medicine, for treating hereditary angioedema (HAE). The results indicate that donidalorsen significantly reduced the number of attacks in patients compared to placebo. These findings will be presented at the ACAAI Annual Scientific Meeting in New Orleans from November 4-8. The study's success positions donidalorsen for advancement into Phase 3 development, reinforcing Ionis' commitment to innovative therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Ionis Pharmaceuticals reported total revenues of $133 million for Q3 2021, reflecting a strategic focus on expanding its late-stage pipeline, now featuring seven Phase 3 programs. Despite a net loss of $48 million, the company maintained a robust cash position of $2 billion. Key developments included commencing the Phase 3 CORE study of olezarsen and advancements in the pipeline with multiple catalysts expected in 2022. However, the tofersen Phase 3 VALOR study did not meet its primary endpoint, although secondary endpoints showed favorable trends.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
Rhea-AI Summary

Ionis Pharmaceuticals announces the initiation of the CORE study, a pivotal Phase 3 clinical trial for olezarsen, targeting severe hypertriglyceridemia (triglyceride levels ≥ 500 mg/dL). This life-threatening condition affects millions, leading to pancreatitis and cardiovascular risks. The CORE study aims to evaluate olezarsen's efficacy against placebo, with primary endpoints focused on reducing fasting triglyceride levels over six months. Previous Phase 2 trials demonstrated significant reductions in triglycerides and a favorable safety profile. The broad olezarsen program plans to enroll over 1500 patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
-
Rhea-AI Summary

Ionis Pharmaceuticals has scheduled a live webcast to discuss its Q3 2021 financial results and business progress on November 3, 2021, at 11:30 a.m. ET. This session will provide insights into the company's pipeline developments and financial performance, contributing to its position in the RNA-targeted therapy market. The webcast is accessible to interested parties via Ionis's official website, with a replay available for a limited time afterwards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
-
Rhea-AI Summary

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced the topline results from Biogen's Phase 3 VALOR study of tofersen, an antisense medicine for SOD1 amyotrophic lateral sclerosis (ALS). Although the primary endpoint was not met, secondary measures indicated trends favoring tofersen. The study involved 108 participants, showing 38% and 67% differences in key biomarkers for faster and slower progressors, respectively. Biogen plans to engage regulatory bodies for next steps, while expanding its early access program for SOD1-ALS patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.82%
Tags
Rhea-AI Summary

Ionis Pharmaceuticals (NASDAQ: IONS) will present 14 posters and two symposiums at the 3rd European ATTR Amyloidosis meeting from September 6-8, 2021. Highlighting advancements in its ATTR amyloidosis portfolio, the presentations will focus on the investigational antisense medicine, eplontersen, which is being evaluated in two phase 3 trials for transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN). Ionis aims to enhance treatment options for patients impacted by this disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences
-
Rhea-AI Summary

Ionis Pharmaceuticals (Nasdaq: IONS) announced its participation in upcoming virtual investor conferences, including the 2021 Wells Fargo Healthcare Conference on September 10, the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, and the Bank of America Global Healthcare Conference 2021 on September 15. Presentation details may change, with updates available on the company's website. A live webcast will be offered, with replays accessible within 48 hours. Ionis is a leader in RNA-targeted therapy, with three marketed medicines and a strong pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
conferences
-
Rhea-AI Summary

Ionis Pharmaceuticals reported Q2 2021 financial results, with total revenues of $126 million and a net loss of $36 million (non-GAAP). The company is well capitalized, ending the quarter with $2.1 billion in cash and investments. Key advancements include full enrollment in the Phase 3 NEURO-TTRansform study and ongoing studies for tofersen and pelacarsen. Ionis aims for more than $600 million in revenue for 2021, while operational changes have streamlined costs. The company anticipates significant data readouts in H2 2021, potentially leading to numerous new product launches by 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Ionis Pharmaceuticals announced significant progress for pelacarsen, a potential treatment for lipoprotein(a)-driven cardiovascular disease, as the Lp(a) HORIZON study reached 50% enrollment with 4,000 participants. This Phase 3 study aims to support the drug's indication for reducing cardiovascular risk. Ionis received a $25 million milestone payment from Novartis and is eligible for up to $675 million in additional milestones, along with mid-teens to low 20% royalties on pelacarsen sales. This investigational medicine utilizes LICA technology to target elevated Lp(a) levels, a significant risk factor for cardiovascular diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none

FAQ

What is the current stock price of Ionis Pharmaceuticals (IONS)?

The current stock price of Ionis Pharmaceuticals (IONS) is $35.63 as of December 20, 2024.

What is the market cap of Ionis Pharmaceuticals (IONS)?

The market cap of Ionis Pharmaceuticals (IONS) is approximately 5.5B.

What does Ionis Pharmaceuticals specialize in?

Ionis Pharmaceuticals specializes in the discovery and development of antisense drugs to treat complex diseases, focusing on cardiovascular, metabolic, neurological, and rare diseases.

Where is Ionis Pharmaceuticals located?

Ionis Pharmaceuticals is headquartered in Carlsbad, California.

What are some key products developed by Ionis Pharmaceuticals?

Key products include Spinraza for spinal muscular atrophy, Qalsody for ALS, Tegsedi for ATTR amyloidosis, and Waylivra for cardiology in Europe.

What is the latest development in Ionis' pipeline?

Ionis is advancing olezarsen, an investigational therapy for familial chylomicronemia syndrome, which has shown promising Phase 3 trial results.

Who are some of Ionis' key partners?

Ionis has strategic partnerships with companies like Biogen and AstraZeneca, helping to bring their innovative therapies to market.

How does Ionis Pharmaceuticals contribute to RNA therapy innovation?

Ionis is a pioneer in RNA-targeted therapies, driving advancements in antisense technology and gene editing to develop treatments for serious diseases.

What is olezarsen and what does it treat?

Olezarsen is an RNA-targeted investigational medicine being developed to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels.

How can I learn more about career opportunities at Ionis Pharmaceuticals?

Visit the Ionis Pharmaceuticals website at www.ionispharma.com for more information on career opportunities and to apply for open positions.

What recent clinical trials has Ionis Pharmaceuticals announced?

Ionis recently announced positive results from trials involving olezarsen for FCS and donidalorsen for hereditary angioedema, among others.

How does Ionis Pharmaceuticals support patients with rare diseases?

Ionis develops targeted therapies for rare diseases, providing innovative treatments where few or no options previously existed, significantly improving patient outcomes.

Ionis Pharmaceuticals, Inc.

Nasdaq:IONS

IONS Rankings

IONS Stock Data

5.55B
154.36M
0.77%
103.25%
7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CARLSBAD